doi: 10.1080/17474086.2023.2268271
This broad regulatory activity includes upregulation of tissue repair genes, collagen synthesis pathways, antioxidant defense systems, and anti-inflammatory signaling networks, alongside simultaneous downregulation of genes associated with tissue destruction, inflammation, and fibrosis
(2007) 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
Theyve got some rules to make sure these treatments are used the right way, which is key to avoiding any potential health risks and getting the most out of the meds
10.1080/10408391003699550 123 JelsingJ.VrangN.HansenG.RaunK.Tang-ChristensenM.KnudsenL
At equivalent diabetes doses, the two medications produce very similar GI side effect rates